- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Appeals court rejects Lilly over Gemzar patent
November 1, 2010
IBJ Staff and Bloomberg NewsWithout an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreBioCrossroads helping laid-off life sciences workers land safely
October 30, 2010
Chris O'MalleyIndiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched
a website that aims to keep that talent in the state.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
MoreIndianapolis-area experts see bright spots amid ongoing real estate weakness
October 23, 2010
Health care shows signs of life, and multi-family buildings continue to hold their own, experts said during a recent IBJ
Power Breakfast.
MoreAnalysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreAnalysts grill Lilly execs on strategy after setbacks
October 21, 2010
J.K. WallWall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted
pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
MoreLilly raises forecast after beating third-quarter profit estimates
October 21, 2010
J.K. WallThe Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with
last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
MoreLilly suspends clinical trials after diabetes treatment fails
October 20, 2010
Bloomberg NewsEli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage
study, the second setback for a Lilly diabetes drug candidate in two days.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreSome Lilly-paid docs sport spotty records
October 20, 2010
J.K. WallEli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other
doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
MoreFDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly to close drug discovery center in Singapore
October 18, 2010
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150
million plan to expand it.
MoreLilly falls short on 'field goal' attempt
October 13, 2010
J.K. WallEli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing
drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
MoreLilly's Erbitux shows mixed results in cancer studies
October 11, 2010
Bloomberg NewsIn combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread
of breast cancer in some patients with a certain type of aggressive tumor.
MoreCoordinating Lilly 'Day of Service' a major undertaking
October 7, 2010
Scott OlsonGetting 8,500 volunteers to where they're supposed to be along Interstate 70 relies on a system of color-coded passes.
By 6 p.m. Thursday, they'll have planted 1,600 trees and 72,000 shrubs and perennials (with photo gallery).
MoreConsultants: Pharma industry facing huge changes
October 6, 2010
J.K. Wall
To date, most analysts say health reform turned out pretty well for
the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver
a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen
over the past three decades.
Drugmakers’ ‘doughnut hole’ deal to shave sales
October 1, 2010
Bloomberg NewsDrugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion
in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
MoreLilly sues drug distributor over generic Zyprexa sales
September 29, 2010
Bloomberg NewsCelesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing
in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More$150M 'North of South' project moving ahead
September 27, 2010
IBJ StaffOfficials are announcing details of an ambitious downtown development planned for 10 acres Eli Lilly and Co. owns near its
Indianapolis headquarters. The project will include a hotel, apartments, restaurants and retail space and a YMCA.
MoreLilly discovers social media
September 22, 2010
J.K. WallEli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate
social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
MoreLilly wins reversal of class action in Zyprexa suit
September 10, 2010
Bloomberg NewsA U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that
Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in
damages.
MoreLilly investing up to $150M in VC funds
September 8, 2010
Bloomberg NewsThe three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each,
and Lilly will contribute as much as 20 percent of the money.
MoreLab used by Lilly, peers accused of animal cruelty
September 8, 2010
IBJ Staff and Associated PressAn investigation found that lab employees kicked, threw, and dragged dogs; lifted rabbits by their ears and puppies by their
throats; violently slammed cats into cages; and exposed animals to toxic chemicals.
MoreCEO says Lilly still not interested in huge acquisitions
September 7, 2010
IBJ Staff and Bloomberg NewsLilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter
said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Ameriana Bank took over Westfield Farmers Market for 2013 and it is held in their parking lot, corner of 32 and Carey road, 5 to 8. I am selling soap and candles there. great market!
B&T certainly has enough of our taxpayer dollars to do this thanks to Mayor Ballard. Given the firm's exceedingly poor reputation in the legal community, the basement would seem a better option.
Should read MAY hire 20 people.
Not a good location for a 300,000 home. 10th Street fumes, buses, noise. Max for this location 150,000.
The state constitution also does not say that the majority has a right to quorum, nor that the minority is required to allow them quorum. In fact, denial of quorum has been a parliamentary maneuver since the establishment of the first parliaments in the early 1600s. The right to deny quorum (and the requirement fore quorum) are to prevent exactly what happened in Indiana: A tyrannical majority pushing through odious, objectionable legislation. Denial of quorum is totally legitimate, and lest we forget, a tactic the GOP has employed many, many times to ensure their issues weren't given short shrift. By allowing the majority to impose "fines" on the minority for exercising the authority the constitution grants them (to deny quorum,) they are violating the constitution.